Cargando…

‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents

INTRODUCTION: Capsular group B Neisseria meningitidis (MenB) is the most common cause of invasive meningococcal disease (IMD) in many parts of the world. A MenB vaccine directed against the polysaccharide capsule remains elusive due to poor immunogenicity and safety concerns. The vaccines licensed f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carr, Jeremy, Plested, Emma, Aley, Parvinder, Camara, Susana, Davis, Kimberly, MacLennan, Jenny M, Gray, Steve, Faust, Saul N, Borrow, Ray, Christensen, Hannah, Trotter, Caroline, Maiden, Martin C J, Finn, Adam, Snape, Matthew D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583083/ https://www.ncbi.nlm.nih.gov/pubmed/33093030 http://dx.doi.org/10.1136/bmjopen-2020-037358

Ejemplares similares

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp
por: Veggi, Daniele, et al.
Publicado: (2020)

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
por: Sereikaitė, Emilija, et al.
Publicado: (2023)

B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents
por: Marshall, Helen S, et al.
Publicado: (2018)

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy
por: Fazio, Cecilia, et al.
Publicado: (2021)

B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis
por: Marshall, Helen S, et al.
Publicado: (2019)

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
por: Esposito, Susanna, et al.
Publicado: (2015)

A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine
por: McDaniel, Angee, et al.
Publicado: (2019)

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
por: Ruiz García, Yara, et al.
Publicado: (2021)

Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010–2016
por: Rodrigues, Charlene M.C., et al.
Publicado: (2018)

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland
por: Mulhall, Robert M., et al.
Publicado: (2018)

Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant
por: Gönüllü, Erdem, et al.
Publicado: (2019)

FHbp variants among meningococci of serogroup B in Italy: Evolution and selective pressure, 2014–2017
por: Lo Presti, Alessandra, et al.
Publicado: (2023)

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents
por: Biolchi, Alessia, et al.
Publicado: (2020)

Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States
por: Banzhoff, Angelika
Publicado: (2017)

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation
por: Kesanopoulos, Konstantinos, et al.
Publicado: (2018)

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
por: Simões, Maria João, et al.
Publicado: (2017)

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016
por: Patton, Monica E., et al.
Publicado: (2017)

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada
por: Breton, Marie-Claude, et al.
Publicado: (2020)

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
por: Biolchi, Alessia, et al.
Publicado: (2019)

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022
por: Rodrigues, C. M. C., et al.
Publicado: (2023)

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
por: O’Ryan, Miguel, et al.
Publicado: (2013)

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans
por: Viviani, Viola, et al.
Publicado: (2023)

The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes
por: Sanders, Holly, et al.
Publicado: (2012)

Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
por: Bodini, Margherita, et al.
Publicado: (2020)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data
por: Beeslaar, Johannes, et al.
Publicado: (2020)

Differentiating vaccine reactions from invasive bacterial infections in young infants presenting to the emergency department in the 4CMenB era: a retrospective observational comparison
por: Channon-Wells, Samuel William, et al.
Publicado: (2022)

02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections
por: Garcia, Yara Ruiz, et al.
Publicado: (2021)

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
por: Stella, Maria, et al.
Publicado: (2019)

2722. Effects of Sex, Age, and Race on Immunogenicity of MenB-FHbp, a Bivalent Meningococcal B Vaccine: A Pooled Evaluation of Clinical Trial Data
por: Beeslaar, Johannes, et al.
Publicado: (2019)

Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine
por: Green, Luke R., et al.
Publicado: (2018)

Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity
por: Bartolini, E., et al.
Publicado: (2020)

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
por: Marshall, Helen S., et al.
Publicado: (2021)

The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study
por: Looker, Katharine J., et al.
Publicado: (2023)

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies
por: Beeslaar, Johannes, et al.
Publicado: (2020)

Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
por: Leduc, Isabelle, et al.
Publicado: (2020)

A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model
por: Argante, Lorenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0dacr3supfqq96mu9lrbk17dch